MHRA issues new batch of Drug Safety Update notices

MHRA issues new batch of Drug Safety Update notices

November 28 2017 The medicines regulator has issued four Drug Safety Updates relating to...

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

October 31 2017 The medicines regulator has issued four drug safety updates (DRU) relating to...

PPIs may add to liver disease problems in people with alcohol dependency, suggests study

PPIs may add to liver disease problems in people with alcohol dependency, suggests study

October 17 2017 Protein pump inhibitors could supress stomach acid secretion to the extent it...

Pregnant women are not always informed of risks associated with sodium valproate

Pregnant women are not always informed of risks associated with sodium valproate

September 26 2017 Almost a fifth of women with epilepsy (18%) who take sodium valproate are not...

Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

September 4 2017 Ibuprofen is associated with increased blood pressure and hypertension compared...

  • MHRA issues new batch of Drug Safety Update notices

    MHRA issues new batch of Drug Safety Update notices

    Tuesday, 28 November 2017 09:47
  • MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    Tuesday, 31 October 2017 20:03
  • PPIs may add to liver disease problems in people with alcohol dependency, suggests study

    PPIs may add to liver disease problems in people with alcohol dependency, suggests study

    Tuesday, 17 October 2017 14:27
  • Pregnant women are not always informed of risks associated with sodium valproate

    Pregnant women are not always informed of risks associated with sodium valproate

    Tuesday, 26 September 2017 14:14
  • Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

    Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

    Monday, 04 September 2017 15:12

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

insulinMay 11 2016

Serious health risks in type 2 diabetes may be reduced more effectively with insulin and metformin than insulin on its own, researchers have suggested.

Combination therapy resulted in a lower risk of death and major adverse cardiac events (MACE) than insulin monotherapy, the retrospective cohort study found. However, any impact on cancer was less pronounced.

The study by researchers from The Institute of Primary Care and Public Health at Cardiff University has been published on PLoS One. They analysed data from 12,020 patients, among whom 6,484 were treated with insulin monotherapy and 5,536 were prescribed insulin plus metformin. Subjects were followed for an average of 3.5 years.

Overall, there were 1,486 deaths, 579 MACE and 680 cancer events, and the corresponding event rates per 1,000 person years were 41.5 deaths, 20.8 MACE and 21.6 cancer events.

When the different cohorts were compared, the adjusted hazard ratios (aHRs) for people using combination therapy compared to insulin monotherapy were 0.60 for all cause mortality, 0.75 for MAC and 0.96 for cancer. When patients were compared in terms of event propensity, the aHRs were 0.62 for deaths, and 0.99 for cancer. For MACE, the propensity aHRs changed with time, being 1.06 before 3.5 years and 1.87 after 3.5 years.

Although the data looked specifically for patients with type 2 diabetes who had either started therapy with insulin either on its own or in combination with metformin, all patients were prescribed at least two different classes of glucose-lowering medication other than insulin. Other exclusion criteria included people who had a yearly average insulin dose greater than 4 units/kg/day, and patients with an existing history of cancer or large vessel disease, such as myocardial infarction, stroke, or angina.

Among the findings of the study were that those prescribed higher dose insulin monotherapy had the highest MACE risk, with an aHR of 1.46 compared to the lowest risk category of low-dose insulin plus metformin. The researchers noted that high-dose insulin was associated with a higher risk of cancer, but the results were not statistically significant.

Discussing the findings, the researchers say: “Among its purported benefits, metformin may be cardioprotective, an effect that cannot be solely explained by its ability to lower blood glucose. Systematic reviews have reported that insulin plus metformin cause improved glycaemic control, less weight gain, and reduced insulin requirements when compared with insulin monotherapy.”

However, the researchers acknowledge that in selecting data from patients who had been initiated on insulin and the fact that metformin may not always be indicated due to other conditions a patient may have, “the population of people receiving insulin in combination with metformin may be healthier than the monotherapy group.”

Link:

SE Holden at al. ‘Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study’. PLoS One. Published online May 6 2016

Clinical News

December 13 2017 The new revalidation process for pharmacists and pharmacy technicians will come into effect from March 30 2018, the General Pharmaceutical Council has announced.
December 7 2015 Pharmacists in Scotland have been asked to share their views on what politicians need to be made aware of ahead of the Scottish Parliament elections in 2016. The Royal Pharmaceutical Society...